

# **Overview – Crohn’s disease: infliximab and adalimumab**

**Issue date: August 2008**

## **Errata**

After issuing the overview to the Appraisal Committee a number of textual errors were identified.

- Please note that D’Haens et al (1999) noted on pages 9 in table 2, page 10 in table 3 and on page 12 in table 4 is not a randomised controlled trial, but is a subgroup analysis of the Targan et al. (1999) trial
- The incorrect attribution of the sensitivity analysis in the critique of Abbott’s submission to the manufacturer instead of the Assessment Group

The following items replace sections of the overview, as indicated:

### Section 3.3.2 Page 21

The Cochrane review noted the relative risk for fistulae healing of 1.87 (95% CI 1.15 to 3.04) in ACCENT II. This corresponds to week 54 data.

### Section 3.6.3 Page 29

The Assessment Group explored a variation of the extrapolation assumptions. It is assumed that patients who responded to adalimumab stayed on treatment for life in the manufacturer's submission. The Assessment Group explored the results of relaxing this assumption and used drop-out rates from the 40 mg (every other week) arm of the CHARM trial.